AOPT-LTL Therapy Improves Melasma via SCF/c-KIT Pathway Inhibition: Study Finds
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-09-12 15:15 GMT | Update On 2025-09-12 15:15 GMT
Advertisement
China: A new study has revealed that AOPT-LTL therapy significantly improves melasma by reducing melanogenesis, inflammation, angiogenesis, mast cell infiltration, and collagen degeneration, likely via inhibition of the SCF/c-KIT signaling pathway.
The study, led by Bingrong Zhou and colleagues from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China, was published in the
To explore this, the investigators first developed an animal model of melasma using guinea pigs exposed to progesterone injections and ultraviolet B radiation. Animals were then treated with three sessions of AOPT-LTL therapy administered weekly. Alongside this preclinical work, 20 patients with melasma underwent three monthly sessions of the same treatment. Their progress was evaluated using the Modified Melasma Area and Severity Index (mMASI) and the Erythema Index (EI).
The study led to the following findings:
- In the animal model, AOPT-LTL treatment significantly reduced pigmentation and suppressed genes associated with melanin production.
- The therapy decreased mast cell infiltration and lowered the expression of inflammatory and angiogenic factors.
- By inhibiting angiogenesis and reducing collagen breakdown, the treatment improved skin quality and alleviated signs of photoaging.
- AOPT-LTL also blocked the SCF/c-KIT signaling pathway, which regulates mast cell activity and proliferation, suggesting a key molecular mechanism behind its effects.
- Clinical results were consistent with the experimental findings, showing clear therapeutic benefits in patients.
- After three sessions, patients experienced reduced melanin levels and erythema, along with improved mMASI and EI scores.
- The improvements demonstrated both lightening of pigmentation and reduced redness, supporting its effectiveness in enhancing skin tone and texture in melasma.
The authors emphasized that AOPT-LTL therapy offers multiple benefits beyond pigment reduction, targeting inflammation, angiogenesis, and structural degeneration, which are all key processes involved in melasma pathology. By acting on several pathways simultaneously, it may provide a more comprehensive approach compared to conventional treatment modalities.
However, the researchers also acknowledged certain limitations. The study lacked direct head-to-head comparisons with conventional IPL methods, making it difficult to quantify its relative advantages. The sample size of patients was small, and the follow-up period was short, meaning long-term recurrence rates could not be fully assessed. Further laboratory studies are also required to confirm the precise mechanisms of mast cell inhibition observed in vivo.
"The study demonstrated that AOPT-LTL therapy can effectively treat melasma through its broad-spectrum action on melanogenesis, inflammation, vascular changes, and collagen degradation. With its ability to target multiple biological pathways, it shows promise as a novel therapeutic option for patients with melasma, although larger and longer clinical trials are needed to validate its long-term efficacy and safety," the authors concluded.
Reference:
Wang, J., Wang, X., Gu, L., Shi, Z., Xu, Z., Shen, S., Gu, L., Chen, L., Ju, L., Jin, C., Zhou, B., & Hua, H. (2025). Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study. Journal of Cosmetic Dermatology, 24(9), e70443. https://doi.org/10.1111/jocd.70443
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.